US20110223264A1 - Substancefor Restoring Normal Co-expression and Interaction Between the LOX and NRAGE Proteins - Google Patents

Substancefor Restoring Normal Co-expression and Interaction Between the LOX and NRAGE Proteins Download PDF

Info

Publication number
US20110223264A1
US20110223264A1 US12/091,768 US9176806A US2011223264A1 US 20110223264 A1 US20110223264 A1 US 20110223264A1 US 9176806 A US9176806 A US 9176806A US 2011223264 A1 US2011223264 A1 US 2011223264A1
Authority
US
United States
Prior art keywords
extract
lox
nrage
expression
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/091,768
Other languages
English (en)
Inventor
Charbel Bouez
Claudine Gleyzal
Isabelle Orly
Valerie Andre
Pascal Sommer
Corinne Reymermier
Odile Damour
Eric Perrier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
UNIVERSITE' CLAUDE BERNARD LYON 1 (UCBL 1)
UNIVERSITE' CLAUDE BERNARD LYON 1 (UCBL1)
Centre National de la Recherche Scientifique CNRS
BASF Beauty Care Solutions France SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNIVERSITE' CLAUDE BERNARD LYON 1 (UCBL 1), UNIVERSITE' CLAUDE BERNARD LYON 1 (UCBL1), Centre National de la Recherche Scientifique CNRS, BASF Beauty Care Solutions France SAS filed Critical UNIVERSITE' CLAUDE BERNARD LYON 1 (UCBL 1)
Assigned to UNIVERSITE' CLAUDE BERNARD LYON 1 (UCBL 1), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE reassignment UNIVERSITE' CLAUDE BERNARD LYON 1 (UCBL 1) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: REYMERMIER, CORINNE, GLEYZAL, CLAUDINE, SOMMER, PASCAL, ANDRE', VALERIE, BOUEZ, CHARBEL, DAMOUR, ODILE, ORLY, ISABELLE, PERRIER, ERIC
Assigned to UNIVERSITE' CLAUDE BERNARD LYON 1 (UCBL1), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), BASF BEAUTY CARE SOLUTIONS FRANCE SAS reassignment UNIVERSITE' CLAUDE BERNARD LYON 1 (UCBL1) CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE SECTION PREVIOUSLY RECORDED ON REEL 021915 FRAME 0127. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE RIGHT, TITLE AND INTEREST IN APPLICATION OF LETTERS PATENT SERIAL NO. 12/091768. Assignors: REYMERMIER, CORINNE, GLEYZAL, CLAUDINE, SOMMER, PASCAL, ANDRE, VALERIE, BOUEZ, CHARBEL, DAMOUR, ODILE, ORLY, ISABELLE, PERRIER, ERIC
Publication of US20110223264A1 publication Critical patent/US20110223264A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9778—Gnetophyta, e.g. Ephedraceae [Mormon-tea family]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/596—Mixtures of surface active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Definitions

  • the invention relates to the use of a substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins.
  • homeostasis is maintained by a balance between cell proliferation, cell differentiation towards a defined function, and programmed or unprogrammed cell death.
  • the skin for example, can be considered as an organ of which one specific function is to protect the organism from external aggressions. Impermeability to the outside is assured by a highly keratinized corneal layer composed of dead cells.
  • the rhythm of the life of epidermal cells, or keratinocytes is therefore governed by a succession of changes leading to this differentiation into keratinized and dead cells: (1) maintenance of initiator cells (“stem” cells of the basal cell layer of the epidermis), (2) asymmetric division (each stem cell giving two sister cells), (3) differentiation (formation of the suprabasal cell layers of the epidermis from one of the “initiator sister” cells), (4) acquisition of a resistance to apoptotic cell death, (5) change into cornified cells, and (6) programmed cell death of the upper cell layers of the epidermis. Any modification of this balance can be pathological.
  • LOX belongs to the family of the lysyl oxidases (LOs), which are amine oxidases dependent on copper. 5 LO genes have been characterized to date: LOX, LOXL, LOXL2, LOXL3 and LOXL4. Where LOX is known for its role in the crosslinking of collagen ex vivo and in vivo, LOXL is clearly associated with the homeostasis of elastic fibers. The in vivo role of the other isoforms is not known.
  • LOs are synthesized by a variety of cells such as fibroblasts, smooth muscle cells, endothelial cells and keratinocytes. This enzyme is therefore present in numerous tissues such as the skin, the liver, the kidneys, the spleen and the aorta, at both extracellular and intracellular levels.
  • LOX extracellular matrix
  • ECM extracellular matrix
  • ⁇ -aminopropionitrile binds to the active site of LOX in competition with alkylamine substrates; LOs use ⁇ -APN as substrate, thereby forming a Schiff base but without releasing the aldehyde product, which blocks the active site covalently without having an effect on synthesis.
  • said document relates to lysyl oxidases as a whole and not specifically to the LOX isoform; furthermore, it relates exclusively to inhibition of the dedifferentiation of cells cultivated in vitro, providing no teaching on the role of lysyl oxidases, or a fortiori of LOX, in maintenance of the balance between proliferation, differentiation and apoptosis, nor does it provide any teaching on novel partners or substrates for lysyl oxidases or LOX.
  • LOX has been located in the epidermis, its expression being regulated as a function of the level of differentiation of keratinocytes (Noblesse et al., Lysyl oxidase-like and lysyl oxidase are present in the dermis and epidermis of a skin equivalent and in human skin and are associated to elastic fibers, J. Invest. Dermatol., 2004, 122, 621-630).
  • the studies carried out hitherto have not made it possible to define the role of LOX in keratinocytes or to search for its partners in these cells, which make little or no collagen or elastin.
  • the LOX gene is clearly associated with maintenance of the non-tumoral phenotype of cells.
  • the LOX enzyme is a suppresser of the ras oncogene and that somatic mutations in the gene are associated with various cancers (Contente et al., Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras, Science, 1990, 249, 796-798; Csiszar et al., Somatic mutations of the lysyl oxidase gene on chromosome 5q23.1 in colorectal tumors, Int. J. Cancer, 2002, 97, 636-642).
  • LOX probably acts according to the availability and regulation of its cellular substrates and partners, but the latter are still unknown to those skilled in the art.
  • apoptosis is used to describe a particular form of cell death whose morphological characteristics differ from those of necrosis.
  • Apoptosis is a process of programmed cell death that requires the acquisition of caspases.
  • the cells acquire particularly remarkable morphological characteristics, such as condensation of the chromatin and fragmentation of the nucleus, leading to their self-destruction and their elimination from the tissue without damaging the adjacent cells.
  • Apoptosis corresponds to the natural death of cells in the course of their development or during homeostasis.
  • the prior art provides information about a number of agents and mechanisms that are involved in regulating the cell cycle via the cellular processes of apoptosis and differentiation.
  • the NRAGE protein comprises 778 amino acids. In the central region it carries a first domain characteristic of the MAGE proteins: the MAGE homology domain (MHD-1), and in the N-terminal region it carries a second domain: MHD-2, present only in certain isoforms. These two domains have zones rich in lysyl residues. Between these two domains there is a region called IRD (interspersed repeat domain), which does not exist in any other protein currently known.
  • MHD-1 MAGE homology domain
  • MHD-2 MHD-2
  • the NRAGE protein is involved in controlling apoptosis via different pathways.
  • NRAGE By interacting with p75NTR, which is the “low affinity” receptor of neutrophilic factors (NGF) or TNF, NRAGE can block the progression of the cell cycle and thus is proapoptotic via the caspase pathway.
  • NNF neutrophilic factors
  • NRAGE is also proapoptotic by interacting with cytoplasmic inhibitors of apoptotic proteins, IAP.
  • NRAGE can also act directly on the activity of nuclear homeo factors, such as the factors Msx and Dlx, which take part in the morphogenic regulation of tissues.
  • NRAGE Although the expression of NRAGE is ubiquitous, the prior art does not refer to its presence in the skin, nor does it provide any data giving information about a possible relationship between LOX and apoptosis or about a link between LOX and NRAGE.
  • the prior art does not provide the identity of novel partners or substrates for LOX, especially those taking part in maintenance of the cellular balance between proliferation, differentiation and apoptosis; moreover, the prior art does not provide the identity of these novel partners or substrates either in epithelial cells (particularly keratinocytes) or in any other cell type.
  • the prior art gives no information about the possible variations in the expression of LOX in the epidermis (especially LOX expressed by keratinocytes) as a function of age or of the existence or non-existence of exposure to UV or other types of aggression, or in the case of diseases affecting the skin (psoriasis, graft-versus-host reaction, cancers, etc.).
  • the prior art does not provide information about the possible presence of NRAGE in the skin, whether it be healthy skin, skin altered by age or UV or subjected to other types of aggression, or diseased skin.
  • the prior art does not offer known models for studying NRAGE in cells of epithelial origin or in the epidermis.
  • the prior art does not provide a model for identifying active principles capable of modulating the expression of LOX and/or NRAGE in keratinocytes.
  • LOX is expressed in the epidermis, its expression being regulated as a function of the level of differentiation of the keratinocytes (Noblesse et al., 2004).
  • the prior art therefore fails to provide active principles capable of modulating the expression of intracellular partners for LOX (such as NRAGE), which may or may not be associated with modulation of the expression of LOX for the purpose of acting on cell regulation. In this context it is also very difficult to obtain objective criteria for judging the impact of these active principles.
  • LOX such as NRAGE
  • the main object of the invention is to solve the technical problems referred to above, especially the technical problem relating to the provision of a method of identifying active principles for improving the interaction between the LOX and NRAGE proteins in cases where the interaction between LOX and NRAGE is absent or altered.
  • the aim of the invention is to regulate the cellular balance between proliferation, differentiation and apoptosis in cases where it is disturbed, as in the case of skin altered by age or UV or subjected to other types of aggression, and/or in the case of pathological situations such as psoriasis, eczema, graft-versus-host reaction, lichen planus and/or cancerous diseases.
  • the invention further relates to the use of an active principle that modulates the expression of LOX and/or NRAGE for regulating the cellular balance between proliferation, differentiation and apoptosis, particularly in cases where it is disturbed, as in the case of skin altered by age or UV or subjected to other types of aggression, and/or in the case of pathological situations such as psoriasis, eczema, graft-versus-host reaction, and cancerous scars and/or diseases.
  • the invention relates to active principles for improving the interaction between the LOX and NRAGE proteins in cases where the interaction between LOX and NRAGE is absent or altered.
  • the invention makes it possible to solve the technical problem that consists in providing a method of locating the expression of NRAGE and following this expression, especially on a cellular model of skin.
  • the invention makes it possible to solve the technical problem that consists in providing a method of diagnosing a state associated with poor regulation of the interaction between LOX and NRAGE.
  • LOX the isoform of the human protein lysyl oxidase, LOX, as defined in particular by the amino acid sequence SEQ ID no. 1;
  • NRAGE the human protein NRAGE as defined in particular by the amino acid sequence SEQ ID no. 2;
  • modulation of the expression of LOX modulation of the gene coding for LOX, especially modulation of the expression of the messenger RNA coding for LOX, but also modulation of the synthesis of LOX from this messenger RNA, as well as modulation of the activity of LOX;
  • modulation of the expression of NRAGE modulation of the gene coding for NRAGE, especially modulation of the expression of the messenger RNA coding for NRAGE, but also modulation of the synthesis of NRAGE from this messenger RNA, as well as modulation of the biological effect of NRAGE.
  • Active principles which are considered to be effective on LOX are preferably those affording a difference of about ⁇ 50% in the expression of the mRNA of LOX and/or a difference of about ⁇ 15% in the expression of LOX and/or the activity of LOX on a model, comprising at least one cell type exhibiting LOX expression and/or activity, in contact with these active principles, compared with the level of LOX expression and/or activity in a control model (generally without being brought into contact with the active principles).
  • Active principles which are considered to be effective on NRAGE are preferably those affording a difference of about ⁇ 50% in the expression of the mRNA of NRAGE and/or a difference of about ⁇ 15% in the expression of NRAGE and/or the biological effect of NRAGE on a model, comprising at least one cell type exhibiting NRAGE expression and/or activity, in contact with these active principles, compared with the level of NRAGE expression and/or activity in a control model (generally without being brought into contact with the active principles).
  • the present invention relates to the use of an effective amount of at least one substance that modulates the expression and/or activity of at least the LOX protein of sequence ID no. 1, and/or that modulates the expression and/or activity of at least the NRAGE protein of sequence ID no. 2, for the manufacture of a composition for modulating the interaction between LOX and NRAGE in order to regulate the cellular balance between proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered.
  • the invention relates to the use of an effective amount of at least one substance that modulates the expression and/or activity of LOX of sequence ID no. 1, and/or that modulates the expression and/or activity of NRAGE of sequence ID no. 2, for the manufacture of a composition for improving the interaction between the LOX and NRAGE proteins in cases where the interaction between LOX and NRAGE is absent or altered.
  • the invention further relates to the use of an effective amount of at least one substance that modulates the expression and/or activity of at least the NRAGE protein of sequence ID no. 2, and that optionally modulates the expression and/or activity of the LOX protein of sequence ID no. 1, for the manufacture of a composition for preventing or treating at least one state in which the cellular balance between proliferation, differentiation and apoptosis is absent or altered.
  • the expression of LOX and/or NRAGE is modulated in epithelial cells, particularly in keratinocytes.
  • the purpose of said substance is to modulate the interaction between the LOX protein and the NRAGE protein, said interaction occurring especially in the IRD domain of the NRAGE protein.
  • the interaction between LOX and NRAGE comprises the polymerization of NRAGE, particularly its dimerization, by LOX-induced enzymatic catalysis.
  • the interaction between LOX and NRAGE involves the production of H 2 O 2 resulting from the catalytic activity of LOX, the H 2 O 2 then activating other molecules, for example neutral sphingomyelinase or NF-kB.
  • the interaction between LOX and NRAGE involves a non-enzymatic activity of LOX, particularly an activity exerted by the pro-region (A22-D169) of LOX.
  • the purpose of the substance is to treat and/or prevent a condition selected from the group consisting of exposure of cells to a stress, particularly exposure of cells to heat, or exposure of cells to radiation, particularly solar radiation, or exposure of cells to a toxic agent, for example a chemical or microbiological agent, skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer.
  • a condition selected from the group consisting of exposure of cells to a stress, particularly exposure of cells to heat, or exposure of cells to radiation, particularly solar radiation, or exposure of cells to a toxic agent, for example a chemical or microbiological agent, skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer.
  • a condition selected from the group consisting of exposure of cells to a stress, particularly exposure of cells to heat, or exposure of
  • the purpose of the substance is to reduce cell proliferation in the case of hyperproliferation, particularly in a cancer, more particularly an epithelial cancer and most particularly a cutaneous epithelial cancer, of basocellular or spinocellular type, psoriasis or eczema.
  • the purpose of the substance is to reduce apoptosis in the epidermis in the case of substantial apoptosis, particularly during skin ageing, exposure of the skin to a stress, particularly exposure to heat, or exposure of the skin to radiation, particularly solar radiation, or exposure of the skin to a toxic agent, for example a chemical or microbiological agent, or graft-versus-host reaction (GVH).
  • a toxic agent for example a chemical or microbiological agent, or graft-versus-host reaction (GVH).
  • the purpose of the substance is to increase cell proliferation in the case of cell hypoproliferation in the epidermis, particularly during ageing, exposure of the skin to heat, exposure of the skin to radiation, particularly solar radiation, or graft-versus-host reaction (GVH).
  • VH graft-versus-host reaction
  • the purpose of the substance is to stimulate the expression of LOX, and optionally to inhibit the expression of NRAGE, during skin ageing, exposure of the skin to a stress, particularly exposure to heat, or exposure of the skin to radiation, particularly solar radiation, or exposure of the skin to a toxic agent, for example a chemical or microbiological agent, or graft-versus-host reaction (GVH).
  • a toxic agent for example a chemical or microbiological agent, or graft-versus-host reaction (GVH).
  • the purpose of the substance is to stimulate the expression and/or activity of NRAGE, and optionally to inhibit the expression and/or activity of LOX, in the epidermis in order to prevent or treat psoriasis or eczema.
  • the purpose of the substance is to stimulate the expression of LOX and NRAGE in order to prevent or treat a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer, of basocellular or spinocellular type, or lichen planus.
  • said composition is a cosmetic, neutraceutical, dermo-pharmaceutical or pharmaceutical composition.
  • the cellular balance between proliferation, differentiation and apoptosis is the balance between proliferation, differentiation and apoptosis of the keratinocytes.
  • the starting material used to prepare the active principles in the case of plants (preferably roots, stems, barks, flowers, fruits, seeds, germs, gums, exudates, leaves or whole plants) or proteins, may or may not be sterilized by radiation, for example beta or gamma radiation preferably at a dose of 5 kGy, and is then reduced to powder if necessary, for example by grinding at room temperature. The powder is then e.g.
  • a polar solvent for example water, an alcohol, a glycol such as butylene glycol, or a polyol, and/or a mixture of polar solvents, advantageously a mixture of water with an alcohol, glycol or polyol (such as ethanol, glycerol, butylene glycol and other glycols, xylitol, etc.) in variable proportions, preferably a 75/25 or 50/50 water/butylene glycol mixture, or in an apolar solvent, for example an alkane, or a mixture of apolar solvents, or in a mixture of polar and apolar solvents.
  • a polar solvent for example water, an alcohol, a glycol such as butylene glycol, or a polyol, and/or a mixture of polar solvents, advantageously a mixture of water with an alcohol, glycol or polyol (such as ethanol, glycerol, butylene glycol and other glycols, xylitol, etc.)
  • the sample is preferably clarified by decantation or centrifugation and then filtered, preferably on a 0.45 ⁇ m or 0.22 ⁇ m filter.
  • the starting material used to prepare the active principles in the case of characterized molecules (e.g. molecules obtained by synthesis or hemisynthesis, biological molecules obtained by purification), is diluted in a solvent, preferably water or dimethyl sulfoxide (in a concentration preferably of between 10 ⁇ 6 M and 10 ⁇ 2 M and particularly preferably in the order of 10 ⁇ 4 M, or preferably of between 1% weight/weight and 5% weight/weight, depending on the molecules).
  • a solvent preferably water or dimethyl sulfoxide (in a concentration preferably of between 10 ⁇ 6 M and 10 ⁇ 2 M and particularly preferably in the order of 10 ⁇ 4 M, or preferably of between 1% weight/weight and 5% weight/weight, depending on the molecules).
  • a solvent preferably water or dimethyl sulfoxide
  • the active principles obtained by one of the methods described above are used in a final concentration preferably of between 0.01% volume/volume (v/v) and 10% (v/v) and particularly preferably of between 0.1% and 1% (v/v).
  • said substance is selected from the group consisting of a soya extract, an ephedra extract, a hop extract and a cinnamon extract.
  • the invention relates to a method of identifying at least one active principle described above, the purpose of which is in particular to modulate the interaction between LOX and NRAGE in order to prevent or treat at least one state in which the cellular balance between proliferation, differentiation and apoptosis is absent or altered, characterized in that it comprises:
  • analyzing the expression of LOX and/or NRAGE especially to identify an active principle that modulates the expression and/or activity of LOX and/or NRAGE in order to improve the cellular balance between proliferation, differentiation and apoptosis.
  • the invention further relates to a method of identifying at least one active principle for modulating the interaction between LOX and NRAGE in order to improve the interaction between the LOX and NRAGE proteins in cases where the interaction between LOX and NRAGE is absent or altered, characterized in that it comprises:
  • analyzing the expression of LOX and/or NRAGE especially to identify an active principle that modulates the expression and/or activity of LOX and/or NRAGE in order to improve the interaction between the LOX and NRAGE proteins in cases where the interaction between LOX and NRAGE is absent or altered.
  • the balance between the proliferation, differentiation and apoptosis of said living cells capable of expressing the LOX and/or NRAGE protein, or the interaction between the LOX and NRAGE proteins, is absent or altered before they are brought into contact with the active principle.
  • the living cells are epithelial cells, particularly keratinocytes.
  • the method comprises analyzing the expression of the messenger RNAs of LOX and/or NRAGE.
  • the method comprises using quantitative RT-PCR with the following primers in particular:
  • the method comprises analyzing the kinetics of expression of the messenger RNAs, for example by quantitative RT-PCR.
  • the invention further relates to a method for the cosmetic care or therapeutic treatment of a subject in whom the balance between the cellular phenomena of proliferation, differentiation and apoptosis in at least one cell type is disturbed, said method comprising improving the interaction between LOX and NRAGE by the application or administration of a substance that modulates the expression of LOX and/or NRAGE.
  • the invention further relates to a method for the cosmetic care or therapeutic treatment of a subject in whom the interaction between LOX and NRAGE is absent or altered, said method comprising the application or administration of a substance that modulates the expression and/or activity of LOX of sequence ID no. 1, and/or that modulates the expression and/or activity of NRAGE of sequence ID no. 2.
  • the invention further relates to a method for the cosmetic care or therapeutic treatment of a subject presenting with a state in which the cellular balance between proliferation, differentiation and apoptosis is absent or altered, said method comprising the application or administration of a substance that modulates the expression and/or activity of NRAGE, and optionally that modulates the expression and/or activity of LOX.
  • the invention relates to a process for the preparation of a composition, comprising:
  • the mixing of the active principle with at least one excipient in order to produce a cosmetic, neutraceutical, dermopharmaceutical or pharmaceutical composition for preventing or treating at least one state in which the cellular balance between proliferation, differentiation and apoptosis is absent or altered.
  • the invention further relates to a process for the preparation of a composition, comprising:
  • the invention relates to a method of locating NRAGE, comprising the use of at least one anti-NRAGE antibody for detecting and locating the presence of NRAGE, particularly in a model of reconstructed skin comprising at least keratinocytes, or a section of skin, preferably a section of skin originating from a person whose epidermis exhibits a state in which the cellular balance between proliferation, differentiation and apoptosis is absent or altered.
  • the invention relates to the use of an anti-NRAGE antibody for the preparation of a composition for detecting a modulation of the expression of NRAGE at the cellular level, particularly in epithelial cells and preferably in keratinocytes.
  • the purpose of the composition is to detect a state in which the cellular balance between proliferation, differentiation and apoptosis, or the interaction between LOX and NRAGE, particularly in the epidermis, is absent or altered, said state being selected from the group consisting of exposure of cells to a stress, particularly exposure of cells to heat, or exposure of cells to radiation, particularly solar radiation, or exposure of cells to a toxic agent, for example a chemical or microbiological agent, skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer, of basocellular or spinocellular type.
  • a toxic agent for example a chemical or microbiological agent, skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epit
  • the composition also comprises an anti-LOX antibody for detecting a modulation of the expression of LOX at the cellular level, particularly in epithelial cells and preferably in keratinocytes.
  • composition also comprises an anti-LOX antibody for detecting a modulation of the expression of LOX in keratinocytes.
  • the keratinocytes are human keratinocytes.
  • LOX the protein which, being present at the intersection of the proliferation, differentiation and apoptosis pathways, is capable of controlling cellular homeostasis.
  • the inventors have also discovered that the NRAGE protein is present in particular in the epidermis and is expressed in particular by the keratinocytes. This discovery also enables the interaction between LOX and NRAGE to be made an action target for cosmetic care or treatments for restoring cellular homeostasis in situations where it is disturbed.
  • the next step consisted in determining whether the identification of this potential partnership between LOX and NRAGE could correspond to a direct physical interaction between these two proteins. This was carried out in particular by a technique involving co-immunoprecipitation of the LOX and NRAGE proteins produced after transfection of their genes into Cos7 cells. The results obtained on the one hand confirmed the physical interaction between LOX and NRAGE and on the other hand made it possible to specify that LOX interacted with a particular region of NRAGE called IRD (interspersed repeat domain), which is a region specific to NRAGE in the family of the MAGE proteins (cf. Example 3).
  • IRD interspersed repeat domain
  • the inventors identified the expression of NRAGE in both the dermis and the epidermis of the skin (cf. Examples 4 and 5).
  • the inventors used a method of locating the expression of NRAGE in the skin.
  • NRAGE was not expressed homogeneously—as would have been expected of a protein whose presence is generally described as ubiquitous—but in the form of an expression gradient.
  • the epidermis is a stratified epithelium resting on a basal membrane which anchors it to the dermis. Its thickness varies from 60 to 100 ⁇ m on average and it consists of 4 continuous layers, from the deepest to the surface, resulting from a progressive differentiation of the keratinocytes:
  • the basal cell layer (single row of cells)
  • the prickle cell layer (5 to 6 monocellular layers)
  • the horny layer (5 to 10 monocellular layers)
  • NRAGE is absent in the basal cell layer and appears in the first layers of differentiated keratinocytes, the labeling increasing in the horny layers.
  • the labeling of the first suprabasal cell layers of the epidermis corresponds to that observed for LOX, which appears from the basal cell layer upwards.
  • the labeling of LOX decreases in the upper layers of the epidermis, where NRAGE is present, so a distinction is made between the following 3 zones:
  • Observations at the cellular level show that LOX and NRAGE appear at the periphery of the cell, particularly in the submembranous region, NRAGE also appearing in the cytoplasm (cf. Examples 4 and 5).
  • the inventors thus identified, for the first time, the presence of NRAGE in the skin, both in the dermis and the epidermis. They also showed that the epidermis comprises a part in which both the LOX and NRAGE proteins are expressed and share the same location at the cellular level, especially in the keratinocytes, said location being the submembranous peripheral zone (NRAGE also being present in the cytoplasm).
  • the inventors thus demonstrated fulfilment of the conditions for the direct interaction they had identified in vitro to be able to take place in the epidermis in the zone where both LOX and NRAGE are located.
  • the inventors also demonstrated, unexpectedly, that skin ageing and a number of pathological situations are accompanied by disturbances of the expression of LOX and/or NRAGE in the epidermis.
  • the skin of elderly persons is characterized by a hypoproliferative epidermis that is very thin (reduced to a few cell layers) and hyperkeratinized.
  • NRAGE is strongly expressed, is located in the cytoplasm and appears from the first suprabasal cell layer upwards, without an expression gradient.
  • the present invention makes it possible to stimulate the expression (and/or activity) of LOX, with or without inhibiting the expression (and/or activity) of NRAGE, so as to reinduce a regulated differentiation zone and/or apoptosis zone, in particular by restoring a LOX and NRAGE co-expression zone. This also thickens the skin, especially the epidermis.
  • the purpose of the present invention is especially to correct or prevent the effects of skin ageing.
  • GVH is a disease which can arise following allografts of hemopoietic stem cells. It is associated with the effect of the immune cells (lymphocytes) contained in the graft on the patient's normal organs (especially the skin, liver and digestive tract). In the skin it manifests itself in the form of a maculopapular, pruriginous and inflammatory eruption.
  • the present invention makes it possible to stimulate the expression (and/or activity) of LOX, with or without inhibiting the expression (and/or activity) of NRAGE, in order to reinduce a LOX and NRAGE co-expression zone, enabling them to interact and resulting in a reduction in the cutaneous manifestations of GVH, this being accompanied especially by a thickening of the skin, particularly the epidermis.
  • the present invention enables patients suffering from GVH to reduce the cutaneous manifestations of this disease.
  • Lichen is a skin disease of unknown cause which is characterized by the presence of violet, flat, solid, dry and very pruriginous papules a few millimeters in diameter.
  • the inventors identified a very large decrease in the expression of LOX, or even its total absence, and a very irregular expression of NRAGE. These observations certainly reflect a non-existent or very weak level of interaction between the two proteins studied.
  • the present invention makes it possible to stimulate the expression (and/or activity) of LOX, with or without modulating the expression (and/or activity) of NRAGE, in order to reinduce a LOX and NRAGE co-expression zone, enabling them to interact and making it possible to return to a normal epidermal state.
  • the present invention enables patients suffering from lichen planus to treat, reduce or prevent this disease.
  • Psoriasis is a chronic skin disease characterized by erythematosquamous lesions.
  • the fundamental feature of the disease is an increase in the rate of multiplication of the keratinocytes, which is responsible for a more rapid renewal and a thickening of the epidermis.
  • LOX is essentially expressed in the lower part of the epidermis and NRAGE solely in its upper part, the expression of the proteins thus being shifted without there being the overlap zone normally observed in healthy skin.
  • NRAGE is observed only in the cytoplasm and not in the submembranous peripheral zone.
  • inhibition of the expression (and/or activity) of LOX, and/or optionally stimulation, preferably partial stimulation, of the expression (and/or activity) of NRAGE makes it possible in particular to obtain an overlap zone of LOX and NRAGE expression in order to reinduce a regulated proliferation zone that makes it possible to reduce hyperproliferation by promoting apoptosis in the keratinocytes.
  • stimulation of the expression (and/or activity) of NRAGE, and/or inhibition, preferably partial inhibition, of the expression (and/or activity) of LOX makes it possible in particular to obtain an overlap zone of LOX and NRAGE expression in order to reinduce a regulated proliferation zone that makes it possible to reduce hyperproliferation by promoting apoptosis in the keratinocytes.
  • the present invention makes it possible to prevent and/or treat psoriasis or reduce some of its effects.
  • Eczema is a skin complaint characterized clinically by blotches, more or less extensive, localized swellings, and weeping vesicles that subsequently form scabs, accompanied by intense itching. In its chronic phase eczema is complicated by a modification of the skin with thickening. Apoptosis is reduced in the epidermis.
  • NRAGE is weakly expressed and is observed only in the cytoplasm, which certainly reflects a non-existent or very weak level of interaction between the two proteins studied.
  • stimulation of the expression (and/or activity) of NRAGE, and/or inhibition, preferably partial inhibition, of the expression (and/or activity) of LOX makes it possible to increase apoptosis and thereby to reduce some of the effects of eczema.
  • the present invention makes it possible to prevent and/or treat eczema and in particular to reduce some of its effects.
  • epithelial skin carcinoma A distinction is made between two major types of epithelial skin carcinoma:
  • basocellular carcinoma (90% of cases) is an essentially local, slowly developing tumor which virtually never metastasizes. It results from an uncontrolled proliferation of the keratinocytes of the basal cell layer;
  • spinocellular carcinoma (10% of cases) has a much more aggressive local development and can metastasize. It originates from an uncontrolled proliferation of the keratinocytes of the prickle cell layer.
  • the inventors identified the absence of LOX and NRAGE in the invasive cells of the two types of cancer studied (basocellular and spinocellular cancers), with a progressive loss of LOX and NRAGE in the epidermis in the vicinity of the tumors.
  • the inventors also observed that LOX is strongly expressed in the stromal reaction around the tumors, whereas NRAGE is absent in this reaction.
  • stimulation of the expression (and/or activity) of NRAGE and the expression (and/or activity) of LOX makes it possible to restore homeostasis. It is possible to bring about a reversion of the tumoral phenotype, especially in epithelial skin cancers.
  • the inventors provided methods of identifying active principles that modulate the expression of LOX and/or NRAGE in order to restore the control exerted by these proteins via their interaction, for the purpose of identifying active principles for the preparation of compositions, especially cosmetic or pharmaceutical compositions.
  • the expression of LOX is stimulated, with or without inhibiting the expression of NRAGE, in order to reinduce, via modulation of the co-expression of LOX and NRAGE, a regulated differentiation and apoptosis zone that leads to a thickening of the skin.
  • NRAGE In the case of epidermal hyperproliferation (psoriasis, eczema), where NRAGE is underexpressed, the expression of NRAGE is stimulated, with or without (slightly) inhibiting that of LOX, in order to promote apoptosis by reinducing a regulated proliferation zone (LOX/NRAGE overlap) and making it possible to stop the hyperproliferation.
  • apoptosis in the epidermis aged skin, exposure of the skin to a stress, particularly exposure to heat, or exposure of the skin to radiation, particularly solar radiation, or exposure of the skin to a toxic agent, for example a chemical or microbiological agent, or graft-versus-host reaction—GVH)
  • a toxic agent for example a chemical or microbiological agent, or graft-versus-host reaction—GVH
  • the expression of NRAGE is inhibited, with or without stimulating the expression of LOX.
  • the inventors identified the existence of a hitherto unknown link between LOX and apoptosis.
  • the data obtained reflect the antiapoptotic role of LOX in the keratinocytes, said role involving regulation of the proapoptotic protein NRAGE in particular.
  • Active principles were identified in particular by analyzing the expression of the messenger RNAs of LOX and NRAGE, especially on keratinocytes in culture and preferably on human keratinocytes.
  • the active principles whose activity is to be tested are placed in contact with the keratinocytes in culture for a sufficient time and under appropriate conditions for the contact to be effective.
  • the active principles are preferably tested in different concentrations so that any influence of concentration can be detected.
  • the active principles screened in the present invention are of vegetable origin, in particular so as to avoid the problems associated with chemical synthesis.
  • the advantages of active principles of vegetable origin are well known to those skilled in the art, especially in pharmacy, dermopharmacy, neutraceutics and cosmetics.
  • the search for active principles is carried out especially by extracting the total RNAs and then performing quantitative RT-PCR.
  • the preferred primer sequences are those used in Example 13, without implying a limitation.
  • an active principle makes it possible to modulate the expression of the messenger RNA of LOX and/or NRAGE by at least 50% or the expression and/or activity of LOX and/or NRAGE by at least 15%.
  • compositions especially cosmetic, dermopharmaceutical or pharmaceutical compositions.
  • the excipient for these compositions therefore contains e.g. at least one compound selected from the group consisting of preservatives, emollients, emulsifiers, surfactants, moisturizers, thickeners, conditioners, matting agents, stabilizers, antioxidants, texturizing agents, brightening agents, film-forming agents, solubilizers, pigments, colorants, perfumes and sun filters.
  • excipients are preferably selected from the group consisting of amino acids and their derivatives, polyglycerols, esters, cellulose polymers and derivatives, lanolin derivatives, phospholipids, lactoferrins, lactoperoxidases, sucrose-based stabilizers, vitamin E and its derivatives, natural and synthetic waxes, vegetable oils, triglycerides, unsaponifiables, phytosterols, plant esters, silicones and their derivatives, protein hydrolyzates, jojoba oil and its derivatives, liposoluble/water-soluble esters, betaines, amine oxides, plant extracts, sucrose esters, titanium dioxides, glycines and parabens, and particularly preferably from the group consisting of butylene glycol, steareth-2, steareth-21, glycol-15 stearyl ether, cetearyl alcohol, phenoxyethanol, methylparaben, ethylparaben, propylparaben, butylpara
  • compositions are formulated in a form selected from the group consisting of an aqueous or oily solution, a cream or an aqueous or oily gel, particularly in a pot or tube, especially a shower gel or a shampoo; a milk; an emulsion, microemulsion or nanoemulsion, particularly an oil-in-water, water-in-oil, multiple or silicone emulsion; a lotion, particularly in a glass or plastic bottle, a dosing bottle or an aerosol; an ampoule; a syrup; a liquid soap; a hypoallergenic cleansing bar; an ointment; a foam; an injectable solution; an anhydrous, preferably liquid, pasty or solid product, for example in stick form, especially in the form of lipstick; a powder; and a tablet.
  • a form selected from the group consisting of an aqueous or oily solution, a cream or an aqueous or oily gel, particularly in a pot or tube, especially a shower gel or a shampoo;
  • FIG. 1 shows a sequence and a diagram of the NRAGE protein
  • FIG. 2 shows the mean of the results obtained in Example 2 for the two-hybrid interaction
  • FIG. 3 shows the identification of the presence of LOX and NRAGE in reconstructed skin
  • FIG. 4 shows the location of LOX and NRAGE on human skin sections by confocal microscopy
  • FIG. 5 shows the detection of LOX and NRAGE on human skin sections from a 91-year-old donor
  • FIG. 6 shows the detection of LOX and NRAGE in the skin of a person suffering from graft-versus-host reaction
  • FIG. 7 shows the detection of LOX and NRAGE in the skin of a patient presenting with a cancer of basocellular or spinocellular type
  • FIG. 8 shows the detection of LOX and NRAGE in the skin of a patient suffering from lichen planus
  • FIG. 9 shows the identification of the location of LOX and NRAGE in the skin of a patient suffering from psoriasis
  • FIG. 10 shows the identification of the location of LOX and NRAGE in the skin of a patient suffering from eczema.
  • FIG. 11 shows the global labelling of the reconstructed skin with Evans blue (red epidermal layers, blue cells, red fibers of the dermal substrate, dermo-epidermal junction in dotted lines).
  • FIG. 12 shows the immuno-histochemical detection of cyto-keratin 10 on the reconstructed skin (cells strongly expressing the red label, the nuclei in blue, the dermo-epidermal junction in dotted lines).
  • FIG. 13 shows the immuno-histochemical detection of transglutaminase on the reconstructed skin (cells strongly expressing the red label, the nuclei in blue, the dermo-epidermal junction in dotted lines).
  • the invention initially consisted in searching for potential partners for LOX in keratinocytes.
  • the yeast two-hybrid technique (Y2H) was employed.
  • the Y2H system makes it possible to identify and characterize interactions between a “lure” protein and “target” potential partners.
  • the lure was the mature region of LOX fused to the DNA binding domain (BD) of the Gal4 gene.
  • the target or targets were the genes encoded by a complementary DNA library of human keratinocytes, fused to the activation domain (AD) of the Gal4 gene.
  • Interaction of the domains of the lure (LOX) with the domains encoded by a library sequence allows binding and activation of the Gal4 promoter, which controls different genes that confer auxotrophy to AH109 yeasts, enabling growth on deficient medium and activation of the galactosidase activities.
  • a gene coding for a protein that was a candidate partner for LOX was thus identified by virtue of this technique for the possible selection of interactants: the intracellular protein Melanoma Associated Antigen D1 (MAGE-D1) or NRAGE ( FIG. 1 ).
  • the cDNA library of normal human skin keratinocytes in vector pGAD-10 was used.
  • the lure chosen for this screening was LOXmat encoded by the human cDNA region of the LOX enzyme without the signal peptide or the pro-region.
  • the nucleotide sequence was inserted in phase behind the DNA binding domain (BD) of the GAL4 transcription factor in vector pBD-Gal4 Cam.
  • the LOX fragment +494 to +1254 to be inserted was amplified by PCR (polymerase chain reaction), and inserted behind the Gal4 binding domain in vector pGal4-BD, using the following primers:
  • the amplified fragment was initially introduced into vector TOPO and then inserted into pGal4-BD.
  • the AH109 yeasts were transformed by lure plasmid pBD-LOXmat.
  • the transformed yeasts are screened: 6.88 ⁇ 10 6 cfu (growth in deficient medium) in the AH109 yeast, 80 selected clones growing in adenine, histidine, tryptophan and leucine deficient medium, 23 of which were retained for their strong growth.
  • Hela cells are transfected on the one hand by plasmids pAct and pAct-NRAGE and on the other hand by pBind and pBind-LOXmat in the presence of lipofectamine.
  • the luciferase activity is tested after 48 h and the results are expressed as the ratio of luciferase activity to control (empty pBind vector).
  • the experiments are performed in triplicate; the mean of the results obtained is shown in FIG. 2 .
  • Example 1 The hLOX sequence used in Example 1 for yeast two-hybrid screening was inserted in phase behind the Gal4 binding domain in the pBind vector (Promega, Madison, USA) for the mammalian two-hybrid interactions.
  • the NRAGE prey was inserted behind the VP16 Gal4 activation domain in the pAct vector (Promega). It starts at amino acid 152 (nucleotide 458).
  • Cos7 cells are co-transfected for the LOX genes (human complete, human mature region and murine mature region) by the construct pcLOX32-V5His (LOX), pcLOX36-V5His or pcLOX27-V5His and for the NRAGE gene by pNM3-HA (complete NRAGE) or pNM7-HA (IRD region).
  • the transfection is performed in Petri dishes 100 mm in diameter using lipofectamine. After 48 h the transfected cells are lyzed in 500 ⁇ l of lysis buffer.
  • the proteins of the cell lyzates are incubated with either anti-V5 or anti-HA; the anti-V5 or anti-HA monoclonal antibody is added to the cell lyzate at a rate of 1/250 over 1 h 30 min at 4° C., with shaking.
  • the immune complexes (ICs) formed in this way are precipitated with protein G-Sepharose over 1 h at 4° C., with shaking. After three 10-minute washes in lysis buffer and elution in SDS-PAGE buffer, all the ICs are subjected to electrophoresis on a 10% SDS-PAGE gel, followed by Western blotting. Transfer of the ICs to a PVDF (polyvinylidene fluoride) membrane is followed by development:
  • the final detection is effected by chemoluminescence of the HRP.
  • NRAGE NM3-HA
  • LOX 32H human complete form of LOX
  • LOX 36H mature human LOX
  • LOX 27H mature murine LOX
  • the identification was effected in a model of reconstructed skin (MIMESKIN®, Engelhard Lyon, France) prepared from a dermal substrate (collagen/glycosaminoglycans/chitosan, MIMEDISC®, Engelhard Lyon, France) inoculated with normal human fibroblasts, on whose surface normal human keratinocytes were deposited.
  • the samples After 45 days of culture, allowing differentiation of the keratinocytes by exposure at the air-liquid interface, the samples are fixed in Bouin's fixative or formaldehyde and then included in paraffin.
  • anti-NRAGE antibody (goat polyclonal IgG),
  • the immune complexes are detected with a peroxidase-conjugated anti-rabbit IgG using diaminobenzidine as substrate, followed by counterstaining with hematoxylin.
  • FIG. 3 shows the immunohistochemical detection of LOX and NRAGE on the reconstructed skin.
  • the position of the dermo-epidermal junction is indicated by a continuous line, the position of the dermal substrate is indicated by an arrow and the location of the keratinocytes is indicated by an arrowhead.
  • LOX appears from the basal cell layer upwards, persists in the suprabasal cell layers and progressively disappears in the differentiated layers.
  • the expression of NRAGE is slightly shifted; it asserts itself from the non-proliferative suprabasal cell layers upwards and intensifies greatly in the granular and horny layers, where LOX is no longer expressed.
  • the inventors thus demonstrated that the LOX and NRAGE proteins are expressed in the epidermis, with a co-location zone in the prickle cell layers.
  • Frozen sections of samples of normal human skin originating from surgical resection are prepared.
  • the anti-LOX and anti-NRAGE primary antibodies of Example 4 were used to detect the expression of LOX and NRAGE.
  • the secondary antibodies used are:
  • a negative control was prepared in the absence of primary antibodies.
  • the dual labeling was observed using a ZEISS AXIOPLAN 2 LSM510 confocal upright microscope and the images were acquired using ZEISS LSM5 Image Browser software.
  • FIG. 4 shows the immunodetection of LOX and NRAGE in normal human skin by confocal microscopy.
  • Example 4 The observations confirm the results of Example 4, further illustrating the co-location of LOX and NRAGE in the prickle cell layers of the epidermis of normal human skin, with an almost perfect juxtaposition of the expression of LOX and NRAGE.
  • the observations at the cellular level show that LOX and NRAGE appear at the periphery of the cell (in the submembranous peripheral zone), NRAGE also appearing in the cytoplasm.
  • the inventors thus demonstrated fulfilment of the conditions for the direct interaction they had identified in vitro to be able to take place in the epidermis in the zone where both LOX and NRAGE are located.
  • Example 4 An immunohistological study using the protocol described in Example 4 was carried out on sections of human skin originating from 2 donors from different age groups (under 20 years and over 60 years).
  • FIG. 5 shows the labeling performed on the skin of a 91-year-old donor. The observations show a hypoproliferative epidermis that is very thin (reduced to a few cell layers) and hyperkeratinized.
  • NRAGE is strongly expressed, is located in the cytoplasm and appears from the first suprabasal cell layer upwards, without an expression gradient.
  • Example 4 An immunohistological study using the protocol described in Example 4 was carried out on sections of human skin from patients suffering from graft-versus-host reaction (GVH). This study involved 5 different donors.
  • GVH graft-versus-host reaction
  • FIG. 6 identifies an almost total disappearance of LOX in the epidermis (without modification of its expression in the dermis) and a very pronounced presence of NRAGE, which is located in the cytoplasm and appears from the first suprabasal cell layers upwards.
  • Example 4 An immunohistological study using the protocol described in Example 4 was carried out on samples of skin from patients presenting with a basocellular or spinocellular cancer.
  • FIG. 7 shows the following in both types of cancer studied:
  • Example 4 An immunohistological study using the protocol described in Example 4 was carried out on sections of skin from 3 patients suffering from lichen planus.
  • FIG. 8 shows a very large decrease in the expression of LOX in the epidermis, or even its total absence. This disturbance correlates with an irregularity in the expression of NRAGE in the epidermis.
  • Example 4 An immunohistological study using the protocol described in Example 4 was carried out on sections of skin from 5 patients suffering from psoriasis.
  • FIG. 9 is representative of all the sections observed and shows a very strong expression of LOX and a moderate presence of NRAGE in the epidermis, with a more or less homogeneous labeling of the zones in question, showing no expression gradient.
  • LOX is expressed essentially in the lower part of the epidermis and NRAGE solely in its upper part, the expression of the proteins thus being shifted without the overlap zone normally observed in healthy skin.
  • NRAGE is observed only in the cytoplasm and not in the submembranous peripheral zone.
  • Example 4 An immunohistological study using the protocol described in Example 4 was carried out on sections of skin from patients suffering from eczema.
  • FIG. 10 shows a very strong pericellular expression of LOX in the epidermis.
  • NRAGE is weakly expressed and is observed only in the cytoplasm, which reflects a loss of co-location at the cellular level.
  • TUNEL terminal deoxynucleotidyl transferase mediated dUTP nick end labeling
  • the first step consists in labeling the DNA breaks with TdT (terminal deoxynucleotidyl transferase), which catalyzes the polymerization of the fluorescein-labeled nucleotides at the free 3′-OH end of the DNA.
  • the second step consists in detecting the incorporated fluorescein with an alkaline phosphatase-conjugated anti-fluorescein antibody after incubation with the substrate for the latter.
  • the experiment is validated by means of a positive control obtained by fragmentation of the DNA with a DNase solution, and a negative control obtained by depositing phosphate buffer.
  • thermal shock (45° C. ⁇ 0.5° C. for 1 h 30 min) induces pronounced cellular apoptosis
  • the keratinocytes are amplified e.g. in K-SFM (keratinocyte serum-free medium), supplemented with antibiotics, up to the third passage at 37° C. under 5% CO 2 .
  • K-SFM Keratinocyte serum-free medium
  • the cells are inoculated into 96-well plates, e.g. at a rate of 40,000 cells per cm 2 , and cultivated to about 80% confluence.
  • the cells are then cultivated in hypercalcium medium (1.7 mM CaCl 2 at 37° C. under 5% CO 2 ) to induce differentiation of the cells.
  • the starting material used to prepare the active principles in the case of plants (preferably roots, stems, barks, flowers, fruits, seeds, germs, gums, exudates, leaves or whole plants) or proteins, may or may not be sterilized by radiation, for example beta or gamma radiation preferably at a dose of 5 kGy, and is then reduced to powder if necessary, for example by grinding at room temperature.
  • the powder is then dispersed at a rate of 2 to 5% (weight/weight) of powder, preferably 5%, either in a polar solvent, e.g.
  • water or butylene glycol, and/or a mixture of polar solvents advantageously a mixture of water and an alcohol, glycol or polyol (such as ethanol, glycerol, butylene glycol and other glycols, xylitol, etc.) in variable proportions, and preferably a 75/25 or 50/50 water/butylene glycol mixture, or in an apolar solvent, e.g. an alkane, or a mixture of apolar solvents, or in a mixture of polar and apolar solvents.
  • an apolar solvent e.g. an alkane
  • a mixture of apolar solvents e.g. an alkane
  • the sample is clarified by decantation or centrifugation and then filtered, preferably on a 0.45 ⁇ m or 0.22 ⁇ m filter.
  • the starting material used to prepare the active principles in the case of characterized molecules (e.g. molecules obtained by synthesis or hemisynthesis, biological molecules obtained by purification), is diluted in a solvent, preferably water or dimethyl sulfoxide (in a concentration preferably of between 10 ⁇ 6 M and 10 ⁇ 2 M and particularly preferably in the order of 10 ⁇ 4 M, or preferably of between 1% weight/weight and 5% weight/weight, depending on the molecules).
  • a solvent preferably water or dimethyl sulfoxide (in a concentration preferably of between 10 ⁇ 6 M and 10 ⁇ 2 M and particularly preferably in the order of 10 ⁇ 4 M, or preferably of between 1% weight/weight and 5% weight/weight, depending on the molecules).
  • a solvent preferably water or dimethyl sulfoxide
  • the active principles obtained by one of the methods described above are then tested in a final concentration preferably of between 0.01% volume/volume (v/v) and 10% (v/v) and advantageously of between 0.1% and 1% (v/v), for example at 1% (v/v).
  • Incubation in the presence of the cells is advantageously carried out for 24 hours in hypercalcium K-SFM without growth factors.
  • the cells are frozen dry at ⁇ 80° C. after being rinsed in phosphate buffer pH 7.4.
  • the total RNAs are extracted with the SV Total RNA Isolation System (Promega, Meylan, France) for the conditions of 96-well plates according to the manufacturer's protocol.
  • the gene expression is modified by real-time RT-PCR, measuring the expression of each gene relative to actin (housekeeping gene) and expressed in % of the untreated negative control.
  • Quantitative Real-Time RT-PCR Quantitative Real-Time RT-PCR
  • RNAs at 5 ng/ ⁇ l 10 ⁇ l of total RNAs at 5 ng/ ⁇ l are added to 40 ⁇ l of PCR mix (composed of 25 ⁇ l of SYBR Green Buffer Mix 2 ⁇ , 0.5 ⁇ l of enzyme mix, a final concentration of 0.5 ⁇ M of sense primer and a final concentration of 0.5 ⁇ M of antisense primer, and RNase and DNase free water qsp 40 ⁇ l).
  • the RT-PCR proceeds in different steps comprising retrotranscription at 50° C., 30 min, polymerase activation at 95° C., 15 min, and execution of the PCR cycles (95° C., 15 s; 60° C., 30 s; 72° C., 30 s) ⁇ 50 cycles.
  • the percentage stimulation or inhibition is expressed relative to the untreated control (in the absence of test substance).
  • C(T)gene ⁇ x>> denotes the number of cycles necessary to reach the fluorescence threshold of 0.01-0.05 of the gene ⁇ x>>.
  • the ephedra extract is obtained by extraction of the whole plant, especially with a polar solvent such as water or a water/butylene glycol mixture (e.g. 75/25 or 50/50), preferably water.
  • a polar solvent such as water or a water/butylene glycol mixture (e.g. 75/25 or 50/50), preferably water.
  • the hop extract is obtained by extraction of the cones, especially with a polar solvent such as water or a water/butylene glycol mixture (75/25 or 50/50), preferably water.
  • a polar solvent such as water or a water/butylene glycol mixture (75/25 or 50/50), preferably water.
  • the soya extract is obtained by extraction of the seed, especially with a polar solvent such as water or a water/butylene glycol mixture (75/25 or 50/50), preferably water.
  • a polar solvent such as water or a water/butylene glycol mixture (75/25 or 50/50), preferably water.
  • the ephedra extract can be used e.g. in the treatment of diseases such as cancers, preferably cutaneous epithelial cancers (basocellular or spinocellular), or lichen planus, or optionally in the treatment of certain cutaneous manifestations of GVH, or else to reduce the effects of ageing on the skin.
  • diseases such as cancers, preferably cutaneous epithelial cancers (basocellular or spinocellular), or lichen planus, or optionally in the treatment of certain cutaneous manifestations of GVH, or else to reduce the effects of ageing on the skin.
  • the soya extract can be used e.g. in the treatment of diseases such as cancers, like cutaneous epithelial cancers (basocellular or spinocellular), GVH or lichen planus, or for combating or preventing ageing.
  • diseases such as cancers, like cutaneous epithelial cancers (basocellular or spinocellular), GVH or lichen planus, or for combating or preventing ageing.
  • the soya extract can be used especially for combating cell hyperproliferation.
  • the hop extract can be used e.g. in the treatment of diseases such as cancers, like cutaneous epithelial cancers (basocellular or spinocellular), eczema or psoriasis.
  • diseases such as cancers, like cutaneous epithelial cancers (basocellular or spinocellular), eczema or psoriasis.
  • the hop extract can be used especially for combating cell hypo-proliferation.
  • the soya extract and hop extract can be used in association e.g. in the treatment of diseases such as cancers, like cutaneous epithelial cancers (basocellular or spinocellular), or lichen planus.
  • diseases such as cancers, like cutaneous epithelial cancers (basocellular or spinocellular), or lichen planus.
  • the soya extract and ephedra extract can be used in association e.g. in the treatment of diseases such as cancers, like cutaneous epithelial cancers (basocellular or spinocellular), or lichen planus.
  • diseases such as cancers, like cutaneous epithelial cancers (basocellular or spinocellular), or lichen planus.
  • the hop extract and ephedra extract can be used in association e.g. in the treatment of diseases such as cancers, like cutaneous epithelial cancers (basocellular or spinocellular), or lichen planus.
  • diseases such as cancers, like cutaneous epithelial cancers (basocellular or spinocellular), or lichen planus.
  • the experimental conditions used to obtain cells at 80% confluence are identical to those described in Example 13. Differentiation takes place in the presence of calcium (1.7 mM CaCl 2 ) and active principle. An analysis is performed by Q-RT-PCR (method described in Example 13) after 2, 3 and 4 days of incubation.
  • the cinnamon extract is obtained by extraction of the bark, especially with a polar solvent such as water or a water/butylene glycol mixture (75/25 or 50/50), preferably water.
  • a polar solvent such as water or a water/butylene glycol mixture (75/25 or 50/50), preferably water.
  • the cinnamon extract can be used e.g. in the treatment of diseases such as psoriasis.
  • the cinnamon extract and soya extract (whose effect was detected in the previous Example) can be used in association e.g. in the treatment of diseases such as certain cutaneous manifestations of GVH, eczema or psoriasis, or else for reducing the effects of ageing on the skin.
  • the actives were tested on normal human keratinocytes from young subjects, obtained by enzymatic extraction of human biopsies collected after surgical resection and cultivated as monolayers in a K-SFM (keratinocyte serum free medium with supplements) defined medium, supplemented with antibiotics at 37° C. under 5% CO 2 .
  • K-SFM keratinocyte serum free medium with supplements
  • the cells are sown at the second passage in 24-well plates, for example with an amount of 30 000 cells per cm 2 and grown until about 95% confluence.
  • the cell carpets are rinsed with phosphate buffer at pH 7.4 preferably with calcium and magnesium, before being put into contact with the active ingredients to be tested or the reference positive controls diluted in the K-SFM medium, prepared without supplements but with antibiotics.
  • Active ingredients of different origins are tested from 0.1% volume/volume (v/v) to 1% (v/v).
  • An active ingredient from vegetable origin is tested for example at 1% (v/v) and a synthesized molecule is tested for example at 0.1% (v/v)
  • the active ingredient from vegetable origin are extracts which are obtained by macerating plants (preferably roots, rhizomes, stems, barks, flowers, fruit, seeds, germs or leaves) at 2-5% (w/w) in a solvent or a mixture of solvents, advantageously a 100:0 to 0:100 water/(alcohol, glycol or polyol) (such as ethanol, glycerol, butylene glycol and other glycols, xylitol, etc. . . . ) mixture.
  • the obtained extracts are then filtered or distilled in order to recover the soluble fraction which is then filtered at 0.45 ⁇ m preferably.
  • the biotechnological hydrolysates are obtained by fermentation of vegetable extracts in the presence of microorganisms, advantageously from the Lactobacillus or Saccharomyces family. These hydrolysates are then preferably filtered to 0.45 ⁇ m.
  • the incubation is advantageously performed for 24 hours at 37° C. under 5% CO 2 , in a K-SFM medium without growth factors but with antibiotics.
  • the negative controls are either the culture medium by itself, or the culture medium containing from 0.1% (v/v) to 1% (v/v) of the solvent used during the method for extracting the tested extracts.
  • the reference positive control used for inducing cell differentiation is a solution of calcium chloride (CaCl 2 —final concentration of 1.7 mM).
  • the untreated cells (NT control) are dry frozen at ⁇ 80° C. after rinsing with pH 7.4 phosphate buffer. After treatment for 24 hrs in the presence of actives or controls, the cells are dry frozen at ⁇ 80° C. after rinsing with pH 7.4 phosphate buffer.
  • the total RNAs are extracted by means of the SV total RNA isolation system (Promega, Meylan, France) for the conditions of 24-well plates according to the protocol of the manufacturer.
  • Modification of the expression of the genes is achieved by real time RT-PCR which measures the expression of each gene relative to actine (housekeeping gene) and expressed as a % of the untreated negative control (NT).
  • Quantitative Real Time RT-PCR Quantitative Real Time RT-PCR
  • RNAse-free and DNase-free water 10 ⁇ l of 5 ng/ ⁇ l total RNAs are added to 40 ⁇ l of PCR mix (consisting of 25 ⁇ l of SYBR Green Buffer Mix 2 ⁇ , 0.5 ⁇ l of enzyme mix, final 0.5 ⁇ M of sense primer and final 0.5 ⁇ M of antisense primer, RNAse-free and DNase-free water qsp 40 ⁇ l).
  • RT-PCR is performed in different steps including retrotranscription at 50° C., 30 min, activation of polymerase at 95° C., 15 min, performing PCR cycles, (95° C.—15 s, 60° C.—30 s, 72° C.—63 s, 78° C.—30 s) ⁇ 50 cycles.
  • C(T)gene “LOX” meaning the number of cycles required for reaching the fluorescence threshold of 0.01-0.05 of the “LOX” gene.
  • cDNA amounts of each test are relative to the amount of cDNA of actine and then to the negative controls (NT).
  • the results are considered as significative when the measured effect is a modulation by a factor of about 2 (stimulation) or 0.5 (inhibition).
  • NT negative controls
  • the results are considered as significative when the measured effect is a modulation by a factor of about 2 (stimulation) or 0.5 (inhibition).
  • 30 correspond to these criteria under the defined conditions.
  • the reconstructed skin model is in particular achieved according to the following protocol:
  • the active ingredient is advantageously diluted in the culture media described above at 0.5 and 1% and used 3 days after the respective sowing of fibroblasts and keratinocytes (i.e. days 3 to 21 and days 24 to 42).
  • the positive control is preferably made by adding calcium chloride with a final concentration of 1.5 mM during the emerged phase of the reconstructed skins (i.e. day 28-42) in order to stimulate epidermal differentiation.
  • the samples are frozen, included into a thermosensitive resin, and then cryo-cut at 5 ⁇ m.
  • the active ingredient induces the same type of epidermal differentiation as the positive control with a dose-effect relationship.
  • the treated skins have a larger number of keratinocyte layers expressing transglutaminase, in particular in the so-called granular layer.
  • the obtained labelling is more intense and more defined as illustrated in the magnification of the epidermal portion. Quantification clearly demonstrates induction of the protein form after treatment, in particular at 1% active ingredient concentration (2-fold induction).
  • FIG. 11 shows the global labelling of the reconstructed skin with Evans blue (red epidermal layers, blue cells, red fibers of the dermal substrate, dermo-epidermal junction in dotted lines).
  • the active ingredient induces the same type of epidermal differentiation as the positive control with a dose-effect relationship.
  • the treated skins have a larger number of differentiated keratinocyte layers and in particular, an increase in the thickness of the so-called granular layer is noted.
  • an interesting effect was also obtained on the fibroblast density at the dermas treated with ephedra extract.
  • FIG. 12 shows the immuno-histochemical detection of cyto-keratin 10 on the reconstructed skin (cells strongly expressing the red label, the nuclei in blue, the dermo-epidermal junction in dotted lines).
  • the active ingredient induces the same type of epidermal differentiation as the positive control with a dose-effect relationship.
  • the treated skins have a larger number of keratinocyte layers expressing cytokeratin 10 and in particular in the so-called granular layer.
  • FIG. 13 shows the immuno-histochemical detection of transglutaminase on the reconstructed skin (cells strongly expressing the red label, the nuclei in blue, the dermo-epidermal junction in dotted lines).
  • the toxicology tests were performed on the compound obtained according to Example 2, incorporated at a concentration of 10% in a 0.5% xanthan gel, by carrying out an ocular evaluation in the rabbit, by studying the absence of abnormal toxicity by means of a single oral administration in the rat, and by studying the sensitizing power in the guinea-pig.
  • the preparations described above are applied undiluted in a dose of 0.5 ml to the skin of 3 rabbits according to the method recommended by the OECD directive relating to the study of “the acute irritant/corrosive effect on the skin”.
  • the preparations described were given in a single oral administration in a dose of 5 g/kg body weight to 5 male rats and 5 female rats according to a protocol based on OECD directive no. 401 of 24 Feb. 1987 and adapted to cosmetic products.
  • the LD 0 and LD 50 are found to be above 5000 mg/kg. The preparations tested are not therefore classified as dangerous preparations on ingestion.
  • the preparations are classified as non-sensitizing on contact with the skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
US12/091,768 2005-10-28 2006-10-26 Substancefor Restoring Normal Co-expression and Interaction Between the LOX and NRAGE Proteins Abandoned US20110223264A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0511112 2005-10-28
FR0511112A FR2892635B1 (fr) 2005-10-28 2005-10-28 Substance pour restaurer une co-expression et une interaction normales entre les proteines lox et nrage
PCT/FR2006/051117 WO2007048985A2 (fr) 2005-10-28 2006-10-26 Substance pour restaurer une co-expression et une interaction normales entre les proteines lox et nrage

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/051117 A-371-Of-International WO2007048985A2 (fr) 2005-10-28 2006-10-26 Substance pour restaurer une co-expression et une interaction normales entre les proteines lox et nrage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/455,366 Division US9308161B2 (en) 2005-10-28 2012-04-25 Substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins

Publications (1)

Publication Number Publication Date
US20110223264A1 true US20110223264A1 (en) 2011-09-15

Family

ID=36997700

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/091,768 Abandoned US20110223264A1 (en) 2005-10-28 2006-10-26 Substancefor Restoring Normal Co-expression and Interaction Between the LOX and NRAGE Proteins
US13/455,366 Active 2026-11-10 US9308161B2 (en) 2005-10-28 2012-04-25 Substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins
US14/969,783 Abandoned US20160095815A1 (en) 2005-10-28 2015-12-15 Substance for restoring normal co-expression and interaction between the lox and nrage proteins

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/455,366 Active 2026-11-10 US9308161B2 (en) 2005-10-28 2012-04-25 Substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins
US14/969,783 Abandoned US20160095815A1 (en) 2005-10-28 2015-12-15 Substance for restoring normal co-expression and interaction between the lox and nrage proteins

Country Status (9)

Country Link
US (3) US20110223264A1 (zh)
EP (2) EP2345405A1 (zh)
JP (2) JP6058249B2 (zh)
KR (2) KR101609487B1 (zh)
CN (2) CN105963184A (zh)
BR (1) BRPI0617938A2 (zh)
ES (1) ES2622114T3 (zh)
FR (1) FR2892635B1 (zh)
WO (1) WO2007048985A2 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150056310A1 (en) * 2013-08-23 2015-02-26 Basf Beauty Care Solutions France S.A.S. Cosmetic method for increasing collagen expression in skin comprising topically applying an extract of quassia amara
US9308161B2 (en) 2005-10-28 2016-04-12 Basf Beauty Care Solutions France S.A.S. Substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2970415B1 (fr) * 2011-01-14 2013-02-22 Inst Rech Developpement Ird Utilisation de la simalikalactone e comme agent anticancereux
FR3011469B1 (fr) * 2013-10-08 2017-11-10 Basf Beauty Care Solutions France Sas Utilisation cosmetique et/ou dermatologique d'un extrait d'hamamelis virginiana
FR3055546B1 (fr) * 2016-09-05 2020-01-10 Laboratoires Clarins Composition cosmetique comprenant un extrait de fruit d'arbutus unedo.
DE102016216866A1 (de) 2016-09-06 2018-03-08 Henkel Ag & Co. Kgaa Oxidatives Haarfärbemittel mit optimierter Liftleistung
JP7139287B2 (ja) * 2019-06-10 2022-09-20 株式会社ノエビア 固形状油性クレンジング化粧料

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043083A1 (en) * 2000-10-12 2004-03-04 Shi-Yong Ryu Anticancer composition comprising sesquiterpenes isolated from resina ferulae
US20040071791A1 (en) * 2002-10-10 2004-04-15 Tang Jing Hua Psoriasis treatment
US20040185122A1 (en) * 1999-03-19 2004-09-23 Pharmacia Corporation Selective COX-2 inhibition from edible plant extracts
US20050025846A1 (en) * 1994-05-12 2005-02-03 Brown Harold G. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US20050031572A1 (en) * 2001-07-06 2005-02-10 Beiersdorf Ag Cosmetic or dermatological preparations including hops or hop-malt extracts and methods of using same for the prophylaxis and treatment of skin symptoms
US20050181080A1 (en) * 2002-01-14 2005-08-18 Hsu-Shan Huang Chinese traditional medicines for psoriasis
US20050191375A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092076B1 (fr) 1982-04-16 1986-12-17 Societe Des Produits Nestle S.A. Composition lipidique destinée à l'alimentation orale, entérale ou parentérale
JPS61263925A (ja) 1985-05-20 1986-11-21 Kanebo Ltd 制癌補助剤
JPH04271759A (ja) * 1991-02-25 1992-09-28 San Ei Chem Ind Ltd かんきつ類抽出物含有ゲル
FR2699080B1 (fr) 1992-12-11 1995-04-07 Lvmh Rech Utilisation d'un extrait de Simarouba pour l'atténuation des taches pigmentaires cutanées ou pour renforcer la fonction protectrice de la peau, ou pour la préparation d'un milieu de culture de cellules de peau, et composition ainsi obtenue.
WO1994023732A1 (en) * 1993-04-08 1994-10-27 Kambourakis Medicinal Solutions Pty. Limited Therapeutic preparations containing cypress tree extracts and methods of using same
FR2723096B1 (fr) * 1994-07-28 1996-10-18 Univ Picardie Esters associant les acides phenylacetique,3-phenyl-propionique, 4-phenyl-butyrique et n-butyrique au d-mannose, au xylitol et a leurs derives. applications comme medicaments
EP1059086A1 (en) * 1996-11-05 2000-12-13 Malika H. Haque Use of sandal wood oil or constituents of sandal wood oil for the prevention and treatment of warts, skin blemishes and other viral-induced tumors
JPH11147832A (ja) * 1997-11-18 1999-06-02 Noevir Co Ltd 好中球エラスターゼ阻害剤
IN183330B (zh) * 1998-03-23 1999-11-20 Dalmia Ct For Biotechnology
FR2779348B1 (fr) * 1998-06-04 2001-06-08 Fabre Pierre Dermo Cosmetique Nouvelle composition pharmaceutique ou cosmetique, notamment capillaire et procede de traitement cosmetique des affections relevant des desordres angiogeniques
CN1251302A (zh) * 1998-10-19 2000-04-26 郭士元 一种治疗植物神经紊乱的复方叶绿素中药及其制造方法
DE19853425A1 (de) * 1998-11-19 2000-05-25 Martin Roecken Khellin-Zubereitung und deren Verwendung zur topischen Therapie der Psoriasis, ihrer Subtypen, Sonderformen, sowie zur topischen Therapie von Ekzemen
JP2000169383A (ja) * 1998-12-07 2000-06-20 Ichimaru Pharcos Co Ltd 抗アレルギー剤
JP4271759B2 (ja) 1999-01-27 2009-06-03 株式会社岡村製作所 吊り下げ搬送装置
JP2000256345A (ja) * 1999-03-02 2000-09-19 T Hasegawa Co Ltd ポリフェノール類の製造方法
CA2385234A1 (en) * 1999-09-16 2001-03-22 Mcgill University Nrage nucleic acids and polypeptides and uses thereof
AU6976300A (en) * 1999-09-16 2001-04-17 Mcgill University Methods for modulating cell proliferation
ATE285223T1 (de) * 1999-10-08 2005-01-15 Coty Bv Kosmetische wirkstoffzubereitung mit synergistisch erhöhtem radikalschutzfaktor
JP2001151634A (ja) 1999-11-25 2001-06-05 Lion Corp 外用組成物
JP2001172157A (ja) * 1999-12-17 2001-06-26 Shiseido Co Ltd ゼラチナーゼ活性阻害剤および抗老化用皮膚外用剤
JP2001253830A (ja) 2000-03-13 2001-09-18 Lion Corp ヒアルロニダーゼ阻害剤
AU2001261194A1 (en) 2000-05-03 2001-11-12 University Of Hawaii Novel members of the lysyl oxidases family of amine oxidases related applications
FR2810242B1 (fr) * 2000-06-16 2003-01-17 Nuxe Lab Composition cosmetique et/ou dermatologique a base d'extraits de cacao
JP2002020225A (ja) * 2000-07-10 2002-01-23 Naris Cosmetics Co Ltd 保湿組成物
ATE327762T1 (de) 2000-08-31 2006-06-15 Phenolics Llc Effiziente methode zur herstellung von zusammensetzungen, die mit anthocyaninen angereichert sind
FR2817747B1 (fr) * 2000-12-11 2004-12-03 Oreal Utilisation d'au moins une sapogenine, ou d'un extrait naturel en contenant, pour prevenir les signes du vieillissement cutane
US20040044077A1 (en) 2000-12-28 2004-03-04 Chika Katagiri Agents for inhibiting or restoring skin damage caused by drying and method for evaluating the same
JP4524935B2 (ja) * 2001-02-16 2010-08-18 日油株式会社 美白化粧料
KR20020074746A (ko) * 2001-03-21 2002-10-04 주식회사 아미노젠 누에고치 단백질로부터 제조된 항유전독성 및 면역활성증강 효과를 갖는 항암제
FR2824334B1 (fr) 2001-05-03 2003-10-10 Coletica Procede pour tester une substance eventuellement active dans le domaine de la lipolyse et son utilisation principalement cosmetique
US20040219240A1 (en) * 2001-06-20 2004-11-04 Babish John G. Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
JP2003081850A (ja) * 2001-09-14 2003-03-19 Maruzen Pharmaceut Co Ltd 皮膚化粧料
JP4393777B2 (ja) * 2002-03-19 2010-01-06 株式会社ファンケル 抗ヘリコバクター・ピロリ用組成物
FR2837702B1 (fr) * 2002-03-26 2005-01-14 Clarins Lab Composition cosmetique pour le soin de la peau plus particulierement comme soin de nuit
KR20030079492A (ko) * 2002-04-04 2003-10-10 주식회사 바이오시너젠 에리쓰로-1(4'-메톡시페닐)-1,2-프로판디올 또는 이를함유하는 팔각회향의 추출물을 포함하는 염증관련 질환의예방 또는 치료용 약제학적 조성물
JP2004002237A (ja) * 2002-05-31 2004-01-08 Noriko Yagi 老化防止ハーブ
CN1188118C (zh) * 2002-07-23 2005-02-09 中国科学院昆明植物研究所 一种预防或治疗癌症的药物及其用途
JP2004149729A (ja) * 2002-10-31 2004-05-27 Ikeda Shokken Kk 抗酸化剤
WO2004045632A1 (ja) * 2002-11-12 2004-06-03 Kaneka Corporation ペルオキシソーム増殖剤応答性受容体リガンド剤
FR2847267B1 (fr) 2002-11-19 2006-07-28 Coletica Procede de test de l'activite d'une substance potentiellement active pour inhiber l'activite enzymatique de la phospholipase a2
KR20050085218A (ko) * 2002-12-10 2005-08-29 마사야 다나카 피부 외용재 및 그것을 사용한 외용 지양제, 주름 제거도구
KR100467081B1 (ko) * 2002-12-16 2005-01-24 주식회사 코리아나화장품 암백채 추출물을 포함하는 피부 주름 개선용 화장료 조성물
FR2849992B1 (fr) * 2003-01-17 2007-03-16 Inst Phytoceutic Composition pour une administration par voie orale contenant des capsaicinoides
DE10301632A1 (de) * 2003-01-17 2004-07-29 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Kreatin, Kreatinin und/oder seinen Derivaten in Kombination mit Sojabohnenkeimextrakten
CN1215830C (zh) * 2003-03-19 2005-08-24 湖南师范大学 祛斑防皱美白护肤剂
FR2855969B1 (fr) * 2003-06-13 2012-11-30 Coletica Stimulation de l'activite d'une isoforme de lysyl oxydase pour lutter contre certaines pathologies dues a une elastogenese incomplete, absente ou desorganisee
FR2857588B1 (fr) * 2003-07-17 2007-11-30 Oreal Utilisation de beta-endorphine, d'agents exercant une activite beta-endorphine-like en cosmetique et dermatologie
CN1589818A (zh) * 2003-09-04 2005-03-09 朱桂珍 内外两用中药
ES2235642B2 (es) * 2003-12-18 2006-03-01 Gat Formulation Gmbh Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
US8568794B2 (en) 2004-03-12 2013-10-29 Life Science Investments, Ltd. Topical and intravaginal microbicidal and antiparasitic compositions comprising quassinoids or quassinoid-containing plant extracts
MY142017A (en) * 2004-03-19 2010-08-16 Nestec Sa Composition comprising all essential nutrients of a fruit or a plant material with increased stability and bioavailability and process of forming the same
DE602004026647D1 (de) * 2004-09-14 2010-05-27 Ajinomoto Omnichem S A Topische zusammensetzungen mit phosphorylierten polyphenolen
CN100518754C (zh) * 2005-07-22 2009-07-29 山东省医学科学院药物研究所 具抗癌活性的霞草提取物和制备方法及其在制药中的用途
FR2892635B1 (fr) 2005-10-28 2012-11-09 Engelhard Lyon Substance pour restaurer une co-expression et une interaction normales entre les proteines lox et nrage
WO2008142619A1 (en) * 2007-05-17 2008-11-27 Izun Pharmaceuticals Corporation Use of herbal compositions in the protection and enhancement of extracellular matrix components
US8293291B2 (en) 2007-06-25 2012-10-23 Smith Walter P Methods and compositions for reducing the appearance of dynamic facial wrinkles
US20090028895A1 (en) 2007-07-27 2009-01-29 Smith Walter P Methods and compositions for reducing facial lines and wrinkles
FR3009786B1 (fr) 2013-08-23 2017-08-11 Basf Beauty Care Solutions France Sas Utilisation cosmetique ou dermatologique d'un extrait de quassia amara

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025846A1 (en) * 1994-05-12 2005-02-03 Brown Harold G. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US20040185122A1 (en) * 1999-03-19 2004-09-23 Pharmacia Corporation Selective COX-2 inhibition from edible plant extracts
US20040043083A1 (en) * 2000-10-12 2004-03-04 Shi-Yong Ryu Anticancer composition comprising sesquiterpenes isolated from resina ferulae
US20050031572A1 (en) * 2001-07-06 2005-02-10 Beiersdorf Ag Cosmetic or dermatological preparations including hops or hop-malt extracts and methods of using same for the prophylaxis and treatment of skin symptoms
US20050181080A1 (en) * 2002-01-14 2005-08-18 Hsu-Shan Huang Chinese traditional medicines for psoriasis
US20040071791A1 (en) * 2002-10-10 2004-04-15 Tang Jing Hua Psoriasis treatment
US20050191375A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Nam et al, Antiinvasive, antiangiogenic and antitumour activity of Ephedra sinica extract. Phytotherapy Research (2003) Volume 17, Number 1, pp. 70-76. *
Sathiyamoorthy et al, Screening for cytotoxic and antimalarial activities in desert plants of the Negev and bedouin market plant products, Pharmaceutical Biology (1999) Volume 37, Number 3, pp. 188-195. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308161B2 (en) 2005-10-28 2016-04-12 Basf Beauty Care Solutions France S.A.S. Substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins
US20150056310A1 (en) * 2013-08-23 2015-02-26 Basf Beauty Care Solutions France S.A.S. Cosmetic method for increasing collagen expression in skin comprising topically applying an extract of quassia amara

Also Published As

Publication number Publication date
KR20080100333A (ko) 2008-11-17
CN105963184A (zh) 2016-09-28
US20120225141A1 (en) 2012-09-06
CN101365421B (zh) 2016-07-13
JP2009521401A (ja) 2009-06-04
EP2345405A1 (fr) 2011-07-20
EP1948128A2 (fr) 2008-07-30
US20160095815A1 (en) 2016-04-07
KR101500755B1 (ko) 2015-03-17
BRPI0617938A2 (pt) 2011-08-09
FR2892635A1 (fr) 2007-05-04
KR20140083999A (ko) 2014-07-04
KR101609487B1 (ko) 2016-04-05
EP1948128B1 (fr) 2017-03-15
WO2007048985A3 (fr) 2008-04-10
US9308161B2 (en) 2016-04-12
CN101365421A (zh) 2009-02-11
JP6058249B2 (ja) 2017-01-11
JP2015028036A (ja) 2015-02-12
ES2622114T3 (es) 2017-07-05
FR2892635B1 (fr) 2012-11-09
WO2007048985A2 (fr) 2007-05-03

Similar Documents

Publication Publication Date Title
US20160095815A1 (en) Substance for restoring normal co-expression and interaction between the lox and nrage proteins
US8906425B2 (en) Stimulation of the synthesis of the activity of an isoform of lysyl oxidase-like LOXL for stimulating the formation of elastic fibers
JP6215364B2 (ja) ＭＣ−１Ｒ、ＭＣ−２Ｒ、およびμオピオイド受容体調節
KR20070077515A (ko) 탄력섬유형성의 불완전, 결여 혹은 해체로 인한 질병을제어하는 라이실 옥시다제의 동종효소의 활성 촉진
JP6059859B2 (ja) 弾性繊維の形成を刺激するための、ｌｏｘｌ（リシルオキシダーゼ類似）アイソフォームの合成及び活性の刺激
JP4527451B2 (ja) 弾性繊維の形成を刺激するための、ｌｏｘｌ（リシルオキシダーゼ類似）アイソフォームの合成及び活性の刺激
KR100889460B1 (ko) Ｇｄｎｆ를 포함하는 모발의 멜라닌 생성 촉진용 조성물,ｇｄｎｆ를 이용하는 모발의 멜라닌 생성 촉진 방법 및ｇｄｎｆ의 발현정도를 이용하여 모발 멜라닌 생성촉진제를 스크리닝하는 방법
GB2438999A (en) Screening for substances that promote the activity or formation of LOXL
EP1802270B1 (fr) Composition dermatologique et/ou cosmetique contenant des polypeptides
WO2022210296A1 (ja) オキシトシンシグナル増強剤及びオキシトシン誘発性角化細胞増殖促進剤
JP4954450B2 (ja) 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導
JP2015147798A (ja) 弾性繊維の形成を刺激するための、ｌｏｘｌ（リシルオキシダーゼ類似）アイソフォームの合成及び活性の刺激

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITE' CLAUDE BERNARD LYON 1 (UCBL 1), FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOUEZ, CHARBEL;GLEYZAL, CLAUDINE;ORLY, ISABELLE;AND OTHERS;SIGNING DATES FROM 20081010 TO 20081120;REEL/FRAME:021915/0127

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FRAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOUEZ, CHARBEL;GLEYZAL, CLAUDINE;ORLY, ISABELLE;AND OTHERS;SIGNING DATES FROM 20081010 TO 20081120;REEL/FRAME:021915/0127

AS Assignment

Owner name: UNIVERSITE' CLAUDE BERNARD LYON 1 (UCBL1), FRANCE

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE SECTION PREVIOUSLY RECORDED ON REEL 021915 FRAME 0127. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE RIGHT, TITLE AND INTEREST IN APPLICATION OF LETTERS PATENT SERIAL NO. 12/091768;ASSIGNORS:BOUEZ, CHARBEL;GLEYZAL, CLAUDINE;ORLY, ISABELLE;AND OTHERS;SIGNING DATES FROM 20081010 TO 20081120;REEL/FRAME:022212/0062

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE SECTION PREVIOUSLY RECORDED ON REEL 021915 FRAME 0127. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE RIGHT, TITLE AND INTEREST IN APPLICATION OF LETTERS PATENT SERIAL NO. 12/091768;ASSIGNORS:BOUEZ, CHARBEL;GLEYZAL, CLAUDINE;ORLY, ISABELLE;AND OTHERS;SIGNING DATES FROM 20081010 TO 20081120;REEL/FRAME:022212/0062

Owner name: BASF BEAUTY CARE SOLUTIONS FRANCE SAS, FRANCE

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE SECTION PREVIOUSLY RECORDED ON REEL 021915 FRAME 0127. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE RIGHT, TITLE AND INTEREST IN APPLICATION OF LETTERS PATENT SERIAL NO. 12/091768;ASSIGNORS:BOUEZ, CHARBEL;GLEYZAL, CLAUDINE;ORLY, ISABELLE;AND OTHERS;SIGNING DATES FROM 20081010 TO 20081120;REEL/FRAME:022212/0062

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION